Pharmacokinetics of conivaptan use in patients with severe hepatic impairment

PURPOSE: Conivaptan is an intravenous dual V(1A)/V(2) vasopressin antagonist approved for the treatment of euvolemic and hypervolemic hyponatremia. Earlier studies showed that patients with moderate liver disease could be safely treated with conivaptan by reducing the dose by 50%, whereas patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Marbury, Thomas, Fox, Jerry, Kaelin, Byron, Pavliv, Leo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315214/
https://www.ncbi.nlm.nih.gov/pubmed/28243060
http://dx.doi.org/10.2147/DDDT.S125459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315214/
https://www.ncbi.nlm.nih.gov/pubmed/28243060
http://dx.doi.org/10.2147/DDDT.S125459

Ejemplares similares